Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors
Use of Multiscale Omics to Develop a Cohort Database and Study Platform in Breast Cancer Survivors
2 other identifiers
observational
105
1 country
1
Brief Summary
This study gathers information to create a database to improve the ability to diagnose cancer, predict long term health of breast cancer patients, and help develop future treatment products. This study will provide a foundational platform for therapeutic development and intervention studies in the future and may for therapeutic development and intervention studies in the future, and may advance researchers understanding of the contribution gut bacteria to altered circulating estrogens in breast cancer survivors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2021
CompletedFirst Submitted
Initial submission to the registry
July 22, 2021
CompletedFirst Posted
Study publicly available on registry
August 11, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2022
CompletedDecember 30, 2025
December 1, 2025
1.7 years
July 22, 2021
December 23, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Utilization of multiscale omics to build a cohort database for breast cancer survivors
Up to 5 years
Secondary Outcomes (3)
Detection of unique patterns of variance
Up to 5 years
Detection of unique patterns of variance
Up to 5 years
Detection of unique patterns of variance
Up to 5 years
Study Arms (1)
Observational (questionnaire, biospecimen collection)
Participants complete questionnaires over 10 minutes and undergo blood, urine, saliva, and fecal samples collection.
Interventions
Undergo biospecimen collection
Ancillary studies
Complete questionnaires
Eligibility Criteria
Patients diagnosed with breast cancer stages 0 through 3 at time of diagnosis
You may qualify if:
- BCS GROUP
- Female patients diagnosed with breast cancer age 18 - 75, stages 0 through 3 at time of diagnosis
- Who have completed active therapy (including surgery, radiation, and/or chemotherapy)
- Able to speak English and complete surveys and provide the specimen (willing to follow the sample collection instructions)
- Able to read, understand and sign inform consent
- CONTROL GROUP
- Healthy Volunteers age 18 - 75
- Able to speak and read English, complete consent, surveys, and provide specimens
You may not qualify if:
- Unable to give written consent
- Unable to fast before providing blood and urine
- Pregnant women (per participant report) and males
- Unwilling to travel to Mayo Clinic Rochester to provide bio specimens
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Related Links
Biospecimen
Blood, urine, saliva, stool
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brent A. Bauer, M.D.
Mayo Clinic in Rochester
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 22, 2021
First Posted
August 11, 2021
Study Start
April 1, 2021
Primary Completion
December 30, 2022
Study Completion
December 30, 2022
Last Updated
December 30, 2025
Record last verified: 2025-12